WallStreetZenWallStreetZen

NASDAQ: AXDX
Accelerate Diagnostics Inc Stock Forecast, Predictions & Price Target

Analyst price target for AXDX

Based on 1 analyst offering 12 month price targets for Accelerate Diagnostics Inc.
Min Forecast
$1.00+5.82%
Avg Forecast
$1.00+5.82%
Max Forecast
$1.00+5.82%

Should I buy or sell AXDX stock?

Based on 1 analyst offering ratings for Accelerate Diagnostics Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AXDX stock forecasts and price targets.

AXDX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-01

1 of 1

Forecast return on equity

Is AXDX forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is AXDX forecast to generate an efficient return on assets?

AXDX revenue forecast

What is AXDX's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$12.2M+0.91%
Avg 2 year Forecast
$14.5M+20.08%
AXDX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AXDX revenue growth forecast

How is AXDX forecast to perform vs Medical Devices companies and vs the US market?
Company
0.91%
Industry
9.79%
Market
12.87%
AXDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AXDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AXDX vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
AXDX$0.95$1.00+5.82%Hold
NRXS$3.00N/AN/A
SSKN$0.53N/AN/A
QTI$0.81N/AN/A
PAVM$1.77N/AN/A

Accelerate Diagnostics Stock Forecast FAQ

Is Accelerate Diagnostics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: AXDX) stock is to Hold AXDX stock.

Out of 1 analyst, 0 (0%) are recommending AXDX as a Strong Buy, 0 (0%) are recommending AXDX as a Buy, 1 (100%) are recommending AXDX as a Hold, 0 (0%) are recommending AXDX as a Sell, and 0 (0%) are recommending AXDX as a Strong Sell.

If you're new to stock investing, here's how to buy Accelerate Diagnostics stock.

What is AXDX's revenue growth forecast for 2024-2025?

(NASDAQ: AXDX) Accelerate Diagnostics's forecast annual revenue growth rate of 0.91% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.87%.

Accelerate Diagnostics's revenue in 2024 is $12,059,000.On average, 1 Wall Street analysts forecast AXDX's revenue for 2024 to be $263,633,925, with the lowest AXDX revenue forecast at $263,633,925, and the highest AXDX revenue forecast at $263,633,925.

In 2025, AXDX is forecast to generate $313,721,988 in revenue, with the lowest revenue forecast at $313,721,988 and the highest revenue forecast at $313,721,988.

What is AXDX's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: AXDX) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of 10.67%.

What is AXDX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year AXDX price target, the average AXDX price target is $1.00, with the highest AXDX stock price forecast at $1.00 and the lowest AXDX stock price forecast at $1.00.

The Wall Street analyst predicted that Accelerate Diagnostics's share price could reach $1.00 by Apr 1, 2025. The average Accelerate Diagnostics stock price prediction forecasts a potential upside of 5.82% from the current AXDX share price of $0.95.

What is AXDX's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: AXDX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.